56973-41-2

56973-41-2 structure

Name: Withanolide B
Chemical Name: Lycium substance B
CAS Number: 56973-41-2
Molecular Formula: C₂₈H₃₈O₅
Molecular Weight: 454.59800
Catalog: analytical chemistry Analytical reagent Ion chromatography reagent
Create Date: 2016-08-03 18:46:09
Modify Date: 2024-01-11 16:59:40
Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].

Name	Lycium substance B
Synonyms	UNII-9YU877VU8K Withanolide B

Description	Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Stem Cell/Wnt >> Wnt Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Signaling Pathways >> MAPK/ERK Pathway >> ERK Research Areas >> Neurological Disease Signaling Pathways >> Stem Cell/Wnt >> ERK
In Vitro	Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs[1]. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP)[1]. Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs[1]. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells[2]. Cell Viability Assay[1] Cell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2.
In Vivo	Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model[1]. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect[1] Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone.
References	[1]. Kuang Z, et, al. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/β-catenin signaling pathways. Int Immunopharmacol. 2020 Nov;88:106960. [2]. Dubey S, et, al. Improving the inhibition of β-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021 Mar 15;173:56-65. [3]. Sivanandha G, et, al. Enhanced biosynthesis of withanolides by elicitation and precursor feeding in cell suspension culture of Withania somnifera (L.) Dunal in shake-flask culture and bioreactor. PLoS One. 2014 Aug 4;9(8):e104005.

Density	1.206
Molecular Formula	C₂₈H₃₈O₅
Molecular Weight	454.59800
Exact Mass	454.27200
PSA	76.13000
LogP	4.38050

Hazard Statements	H413
RIDADR	NONH for all modes of transport

56973-41-2	105708-64-3
140852-71-7	121923-96-4
113900-78-0	105650-11-1
100046-03-5	107745-54-0
929974-17-4	132246-31-2
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	671-14-7
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1